Paul R Edick
CIK 1531178 · See Remarks · last filed 2025-11-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$32.31M
Companies
9
Total Filings
51
Lifetime Open-Market Net
$1.37M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VTGN | Director | — | $0.25 | — | $0 | 1 | 2025-11-04 |
| XERS | See Remarks | 3,821,494 | $8.46 | $32.31M | $1.30M | 19 | 2024-01-31 |
| MIST | Director | — | $1.05 | — | $0 | 1 | 2020-06-08 |
| Iterum Therapeutics plc (ITRM) Delisted | Director | 2,093 | $0.03 | $63 | $5.2K | 4 | 2019-05-29 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | Director | 214,563 | — | — | $0 | 4 | 2018-06-12 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | 0 | — | — | $0 | 4 | 2018-02-13 |
| Neos Therapeutics, Inc. (NEOS) Delisted | Director | — | $1.15 | — | $0 | 2 | 2017-07-05 |
| LUMOS PHARMA, INC. (NLNK) Delisted | Director | 878 | — | — | $0 | 10 | 2017-05-16 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Chief Executive Officer | 24,636 | — | — | $64.5K | 5 | 2014-11-18 |
Recent Filings · Page 6 of 6
51 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-11-14 | LUMOS PHARMA, INC. (NLNK) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 51–51 of 51
Prev
Page 6 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.